Eric Leire

Eric Leire is the chief executive officer of Genflow Biosciences, a role he has held since February 2020, and is based in Brussels. He is also a non-executive director of InhaTarget Therapeutics, appointed in August 2020, executive chairman of IMMUNETHEP since August 2019 and a non-executive director of BSIM Therapeutics since May 2019.

From March 2017 to January 2019 he was president and chief executive officer of Enochian Biosciences, and between February 2011 and March 2018 he held the same office at DanDrit Biotech USA. He was chief executive of DKTI from 2012 to 2014 and a non-executive director of Novicol International Holding Inc from 2012 to 2020. Earlier he was a partner at NEEI BioMed and at BioFund, chief executive of Paringenix, president and chief executive of APT Therapeutics, a research associate at the Harvard AIDS Institute, a consultant at bioStrategies Group and worked in the pharma division of Pharmacia.

Leire studied medicine at the Université Joseph Fourier (Grenoble I), took an MBA at HEC Paris and studied at Northwestern University - Kellogg School of Management.